Precision BioSciences, Inc.

NASDAQ:DTIL

Biotechnology

Healthcare
$6.91 +1.69%

+$0.11 today

Market cap
$193.04M
Beta
1.28
P/E (TTM)
-1.9
EPS (TTM)
-$3.47
52W Low $3.53High $8.82

Volume 0.27M

Average 0.31M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$65.84M

FY 2025 · Annual

Investing Cash Flow

-$634,000.00

FY 2025 · Annual

Financing Cash Flow

$95.16M

FY 2025 · Annual

+88.6% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(30.6M)(111.64M)(61.32M)7.17M(45.72M)
Depreciation & Amortization10.2M9M8.26M4.58M2.75M
Deferred Income Tax00000
Stock-Based Compensation16.51M19.2M14.04M12.6M10.19M
Change in Working Capital19.58M24.11M(41.49M)(54M)(24.71M)
Accounts Receivables9.51M(232K)(181K)10.42M229K
Inventory00000
Accounts Payables867K153K1.51M(2.1M)(737K)
Other Working Capital9.21M24.19M(42.81M)(62.33M)(24.2M)
Other Non-Cash Items(26.55M)13.57M(3.6M)(28.79M)(8.35M)
Operating Cash Flow(10.85M)(45.75M)(84.11M)(58.45M)(65.84M)
Capital Expenditures(5.8M)(3.32M)(2.28M)(250K)(85K)
Acquisitions (Net)008M60K0
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities(750K)0107K(25K)(549K)
Investing Cash Flow(5.8M)(3.32M)5.83M(215K)(634K)
Debt Repayment2.47M19.81M0(37K)0
Common Stock Issued60.48M74.35M4.99M50.24M95.16M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities7.57M835K401K249K0
Financing Cash Flow70.52M94.99M5.39M50.45M95.16M
Effect of Forex Changes00000
Net Change in Cash53.87M45.91M(72.9M)(8.21M)28.69M
Free Cash Flow(16.66M)(49.07M)(86.39M)(58.7M)(65.93M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$45.7M
+ D&A$2.8M
+ Stock-Based Comp$10.2M
+ Deferred Tax$0
- Working Capital-$24.7M
- Other Non-Cash-$8.3M
= Operating Cash Flow-$65.8M
- Capex-$85.0K
= Free Cash Flow-$65.9M

Analysis

FY2025 free cash flow is -$65.9M. FCF conversion is 144.2% of net income. Operating cash flow was -$65.8M, with capex of -$85.0K. The largest bridge item is Working Capital at -$24.7M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 12, 2026
8-KCurrent reportNov 9, 2026
424B5424B5 filingNov 6, 2026
8-KCurrent reportNov 6, 2026
FWPFWP filingNov 5, 2026

Does DTIL generate free cash flow?

Precision BioSciences, Inc. (DTIL) generated -$65.93M of free cash flow in fiscal 2025.

How much operating cash flow does DTIL produce?

Operating cash flow was -$65.84M, before capital expenditures of $85,000.00.